Physician profile
Tomasz Stankiewicz
NPI 1346654944
$2,663.45
in general payments reported to CMS, 2019-2025
23 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $317 · 2023: $1,273 · 2024: $1,074.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,315 · Education: $32.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,314.56 |
| Education | $32.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $463.87 | 2022-2024 | Ozempic, Wegovy, Rybelsus |
| Amgen INC. | $357.31 | 2022-2024 | Repatha, Otezla, Prolia |
| Pfizer INC. | $344.64 | 2023-2024 | |
| Abbvie INC. | $331.11 | 2022-2024 | Vraylar, Ubrelvy, Qulipta |
| Lilly USA, LLC | $229.66 | 2022-2024 | Jardiance, Mounjaro, Zepbound |
| Glaxosmithkline, LLC. | $177.71 | 2022-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $128.15 | 2023-2024 | Rexulti |
| Astrazeneca Pharmaceuticals Lp | $90.67 | 2023-2024 | Airsupra, Farxiga |
| Novartis Pharmaceuticals Corporation | $82.41 | 2022-2024 | |
| Exact Sciences Corporation | $57.95 | 2023 | Cologuard Collection Kit |
| Bayer Healthcare Pharmaceuticals INC. | $52.73 | 2022-2024 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $46.61 | 2022-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $45.54 | 2024 | Jardiance |
| Radius Health, INC. | $43.36 | 2024 | Tymlos |
| Lundbeck LLC | $35.94 | 2023-2024 | Rexulti |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Antares Pharma, INC. | $34.52 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Merck Sharp & Dohme LLC | $30.88 | 2024 | Capvaxive, Gardasil 9, Gardasil |
| Biohaven Pharmaceutical Holding Company Ltd. | $24.07 | 2022 | |
| Idorsia Pharmaceuticals US INC | $23.51 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $20.64 | 2023 | Camzyos |
| Cranial Technologies, INC | $14.51 | 2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $14.09 | 2023 | |
| Esperion Therapeutics, INC. | $13.57 | 2024 | Nexletol |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tomasz Stankiewicz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.